Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
- 1 August 2019
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 134, 259-267
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca Canada Inc.
- Merck Canada Inc.
This publication has 65 references indexed in Scilit:
- Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-AnalysisJournal of Clinical Oncology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II TrialClinical Cancer Research, 2011
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. OncologyJournal of Clinical Oncology, 2008
- Lung CancerNew England Journal of Medicine, 2008
- Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group BJournal of Clinical Oncology, 2007
- Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patientsAnnals of Oncology, 2006